Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $50.0 million.

  • Lyell Immunopharma's Cash from Financing Activities was N/A to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.6 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is 23.92% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Cash from Financing Activities stood at $50.0 million, which was up 27,222.40% from $183,000 recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Cash from Financing Activities ranged from a high of $393.5 million in Q2 2021 and a low of -$531,000 during Q3 2021.
  • In the last 3 years, Lyell Immunopharma's Cash from Financing Activities had a median value of $310,000 in 2024 and averaged $5.3 million.
  • Over the last 5 years, Lyell Immunopharma's Cash from Financing Activities had its largest YoY gain of 2,089.05% in 2021, and its largest YoY loss of 1,617.14% in 2021.
  • Lyell Immunopharma's Cash from Financing Activities (Quarterly) stood at $7.4 million in 2021, then tumbled by 88.34% to $863,000 in 2022, then declined by 12.05% to $759,000 in 2023, then slumped by 42.42% to $437,000 in 2024, then tumbled by 78.77% to $50.0 million in 2025.
  • Its Cash from Financing Activities was $50.0 million in Q3 2025, compared to $183,000 in Q2 2025 and $1,000 in Q1 2025.